[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334261-105":59,"doc-detail-334261-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","birc5-as-a-prognostic-and-diagnostic-biomarker-in-pan-cancer-an-integrated-analysis-of-expression-immune-subtypes-and-functional-networks","BIRC5 as a prognostic and diagnostic biomarker in pan-cancer - an integrated analysis of expression, immune subtypes, and functional networks","","BIRC5 (Survivin) is a key anti-apoptotic protein implicated in cancer progression and treatment resistance. This study evaluates BIRC5 across 33 cancer types by integrating RNA-seq expression data from TCGA with protein expression data from the Human Protein Atlas. Expression differences between tumor and normal tissues are assessed, and links to molecular and immune subtypes are explored using TISIDB. Prognostic relevance is tested via survival analysis, Cox regression, and ROC-based diagnostic performance, while STRING-derived PPI networks and LUAD functional assays support mechanistic involvement in proliferation, migration, and invasion.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/birc5-as-a-prognostic-and-diagnostic-biomarker-in-pan-cancer-an-integrated-analysis-of-expression-immune-subtypes-and-functional-networks/334261/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/birc5-as-a-prognostic-and-diagnostic-biomarker-in-pan-cancer-an-integrated-analysis-of-expression-immune-subtypes-and-functional-networks/334261.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main research goal of this study on BIRC5?","Question",{"text":112,"@type":113},"To determine whether BIRC5 can serve as a diagnostic and prognostic biomarker across pan-cancer, and to characterize its immune and functional network associations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were expression levels of BIRC5 analyzed across cancer types?",{"text":117,"@type":113},"RNA-seq data from TCGA and protein expression data from the Human Protein Atlas were used to compare tumor versus normal tissues and evaluate expression patterns.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports BIRC5 as a prognostic biomarker?",{"text":121,"@type":113},"Survival analyses showed that higher BIRC5 expression is associated with poorer prognosis across multiple cancers, including LUAD and KIRC, supported by Cox regression.",{"name":123,"@type":110,"acceptedAnswer":124},"What experimental findings were reported for lung adenocarcinoma (LUAD)?",{"text":125,"@type":113},"LUAD functional experiments indicated that BIRC5 upregulation increases cell proliferation, migration, and invasion, while BIRC5 knockdown suppresses these cellular activities.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},334261,1790017416,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","TYPE Original Research PUBLISHED 05 December 2024 DOI 10.3389/fgene.2024.1509342  \nOPEN ACCESS  \nEDITED BY  \nVincenzo Dattilo,  \nMagna Græcia University of Catanzaro, Italy  \nREVIEWED BY  \nClaudia Veneziano,  \nMagna Græcia University, Italy Yao Tian,  \nTianjin Medical University General Hospital, China  \n*CORRESPONDENCE  \nDingyun You,  \n [youdingyun@kmmu.edu.cn](youdingyun@kmmu.edu.cn)[ ](youdingyun@kmmu.edu.cn)Shoujun Deng,  \n [423352657@qq.com](423352657@qq.com)  \n†These authors have contributed equally to this work  \nRECEIVED 10 October 2024  \nACCEPTED 19 November 2024  \nPUBLISHED 05 December 2024  \nCITATION  \nLi G, Wang Y, Wang W, Lv G, Li X, Wang J, Liu X, Yuan D, Deng S and You D (2024) BIRC5 as a prognostic and diagnostic biomarker in pancancer: an integrated analysis of expression, immune subtypes, and functional networks. Front. Genet. 15:1509342 .  \ndoi: 10.3389/fgene.2024.1509342  \nCOPYRIGHT  \n© 2024 Li, Wang, Wang, Lv, Li, Wang, Liu, Yuan, Deng and You. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBIRC5 as a prognostic and diagnostic biomarker in  \npan-cancer: an integrated analysis of expression, immune subtypes, and functional networks  \nGuoyu Li 1†, Yanghao Wang 2†, Weizhou Wang 3†, Guodong Lv 4, Xiang Li 4, Jingying Wang 4, Xiuyu Liu 4, Daolang Yuan 4, Shoujun Deng 5* and Dingyun You 6*  \n1Department of Colorectal Surgery, Yunnan Cancer Hospital, Kunming, Yunnan, China, 2Department of Pathology, The First Afﬁliated Hospital of Kunming Medical University, Kunming, Yunnan, China, 3Department of Orthopedics, The First Afﬁliated Hospital of Kunming Medical University, Kunming, Yunnan, China, 4Clinical College, Kunming Medical University, Kunming, Yunnan, China, 5Department of Thoracic Surgery, Yanan Hospital Afﬁliated to Kunming Medical University, Kunming, Yunnan, China, 6School of Public Health, Kunming Medical University, Kunming, Yunnan, China  \nIntroduction: BIRC5 (Survivin) is a crucial anti-apoptotic protein overexpressed in various cancers, promoting tumor growth and treatment resistance. This study investigates its expression across 33 cancer types and explores its diagnostic, prognostic, and immune-related signiﬁcance.  \nMethods: We analyzed RNA-seq data from TCGA and protein expression data from the Human Protein Atlas. Expression levels were compared between tumor and normal tissues. Correlations with molecular and immune subtypes were explored using TISIDB. Prognostic signiﬁcance was evaluated through survival analysis, Cox regression, and ROC curve analysis. The PPI network was constructed using STRING.  \nResults: BIRC5 was signiﬁcantly overexpressed in tumor tissues across 33 cancer types, with higher expression levels observed in tumors compared to normal tissues. The protein expression analysis revealed a similar trend. BIRC5 expression was signiﬁcantly correlated with various molecular and immune subtypes in multiple cancer types. Survival analysis indicated that high BIRC5 expression was associated with poor prognosis across multiple cancers, including lung adenocarcinoma (LUAD) and kidney renal clear cell carcinoma (KIRC) . ROC analysis showed that BIRC5 exhibited strong diagnostic potential, with high AUC values (>0. 9) in several cancers. The PPI network analysis identiﬁed key interacting proteins involved in the cell cycle and tumor progression, further supporting BIRC5 ’s role in cancer biology. Functional experiments in lung adenocarcinoma (LUAD) revealed that BIRC5 upregulation enhances cell proliferation, migration, and invasion, while its knockdown suppresses these activities.  \nFrontiers","cbCainsMAW5mHvGy","https://ap.wps.com/l/cbCainsMAW5mHvGy","pdf",10324452,16,"English","# Introduction\n# Methods\n# Results\n# Discussion","[{\"question\":\"What is the main research goal of this study on BIRC5?\",\"answer\":\"To determine whether BIRC5 can serve as a diagnostic and prognostic biomarker across pan-cancer, and to characterize its immune and functional network associations.\"},{\"question\":\"How were expression levels of BIRC5 analyzed across cancer types?\",\"answer\":\"RNA-seq data from TCGA and protein expression data from the Human Protein Atlas were used to compare tumor versus normal tissues and evaluate expression patterns.\"},{\"question\":\"What evidence supports BIRC5 as a prognostic biomarker?\",\"answer\":\"Survival analyses showed that higher BIRC5 expression is associated with poorer prognosis across multiple cancers, including LUAD and KIRC, supported by Cox regression.\"},{\"question\":\"What experimental findings were reported for lung adenocarcinoma (LUAD)?\",\"answer\":\"LUAD functional experiments indicated that BIRC5 upregulation increases cell proliferation, migration, and invasion, while BIRC5 knockdown suppresses these cellular activities.\"}]","BIRC5 as a prognostic and diagnostic biomarker in pan-cancer - an integrated analysis of expression, immune subtypes, and functional networks | PDF",1790006037]